Market news

Incyte has delivered a strong multi year share-price run, so the obvious follow up is whether the current valuation is still grounded in the cash the business is expected to generate. With investors weighing fresh product news against a higher starting price, the question is how much of Incyte's future cash flows are already embedded in today's quote. Over the past 3 years the stock has gained 110.9%, which puts pressure on investors to judge whether the cash flow outlook has risen enough to...

Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company’s pipeline has changed substantially over t

Incyte is testing a trendline early buy point while its relative strength line is flashing a bullish signal.

Pablo J Cagnoni, President, Global Head of R&D, on September 15, 2026, sold 23,218 shares in Incyte

Incyte (INCY) drew fresh attention after Ontario agreed to fund MINJUVI for relapsed or refractory follicular lymphoma through its FAST Program, giving eligible patients earlier access while reimbursement reviews continue. For context, Incyte’s share price has climbed 27.0% over the past 90 days and the year-to-date share price return is 23.0%. Meanwhile, the 1-year total shareholder return of 47.1% and 3-year total shareholder return of 106.6% point to momentum that long-term holders have...

Lumentum, WisdomTree, Palomar Holdings, Palantir Technologies and Incyte are among the 15 new stocks today on IBD's elite screens.

Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Incyte stock is trading just below a buy zone as Big Money gives it the stamp of approval.

Incyte (NYSE: INCY) today announced that MINJUVI® (tafasitamab) in the treatment of relapsed or refractory follicular lymphoma (R/R FL) has been funded in the province of Ontario through Ontario's Funding Accelerated for Specific Treatments (FAST) Program. Through this program, eligible patients may gain access to treatment sooner while formal reimbursement processes continue.1,2

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Incyte is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. See why INCY stock is a Buy.

Detailed price information for Incyte Corp (INCY-Q) from The Globe and Mail including charting and trades.

WILMINGTON, Del., September 01, 2026--Incyte to Present at Upcoming Investor Conferences

Incyte (INCY) is back in focus following renewed attention on upcoming ESMO data for its KRAS G12D inhibitor, known as 734, which is being studied in combination with chemotherapy for pancreatic ductal adenocarcinoma. The renewed focus on Incyte comes after a strong run in the share price, with the latest close at US$124.37 and a 90 day share price return of 30.11%. That move sits within a broader trend where the year to date share price return is 22.63%, while total shareholder return over 1...

Incyte (NasdaqGS: INCY) is drawing attention as its KRAS G12D inhibitor '734 heads into new data presentations at ESMO, focused on pancreatic ductal adenocarcinoma. The upcoming ESMO readout is expected to support ongoing Phase 3 trials of '734 in pancreatic cancer, a disease area with high unmet medical need. Interest is heightened after a competitor recently received FDA approval for a therapy targeting a similar pathway in oncology. This spotlight on Incyte shows how much investor...

Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and...

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.